<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655821</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE-II</org_study_id>
    <nct_id>NCT03655821</nct_id>
  </id_info>
  <brief_title>Dose Individualization of Pemetrexed - IMPROVE-II</brief_title>
  <acronym>IMPROVE-II</acronym>
  <official_title>Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the
      treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma. Dosing of
      cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and
      toxicity. Administration of pemetrexed to patients with a creatinine clearance &lt;45 ml/min is
      currently not advised. Pemetrexed is dosed based on body surface area (BSA), while renal
      function and dose are the sole determinants for systemic exposure. This causes 3 major
      issues:

        1. In patients with renal dysfunction, BSA-based dosing may lead to haematological toxicity

        2. Patients have to discontinue treatment due to declining renal function, and are withheld
           effective treatment

        3. Even in patients with adequate renal function (GFR &gt;45 ml/min) treatment may be improved
           by individualized dosing based on renal function, resulting in less toxicity. Also,
           BSA-based dosing may lead to ineffective therapy in patients with above average renal
           function.

      The investigators aim to address these problems.

      Objective: The overall main objective is to develop a safe and effective individualized
      dosing regimen for pemetrexed.

      Study design: IMPROVE-II is an open label, double arm, randomized study to compare renal
      function-based dosing of pemetrexed versus BSA-based dosing on attainment of therapeutic
      exposure.

      Study population: IMPROVE-II includes 94 patients with NSCLC or mesothelioma that are
      eligible for pemetrexed treatment.

      Intervention: patients will be randomized in a 1:1 ratio to Arm A (BSA-based dosing according
      drug label) or to Arm B (renal function based dosing). The renal function-based dose will be
      calculated to reach the target AUC. Pharmacokinetic assessment after administration will be
      performed after the first pemetrexed dose in both arms.

      Main study endpoints: The fraction (percentage) of patients with attainment of therapeutic
      exposure with BSA-based dosing versus renal function-based dosing.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness:

      The investigators consider the extra burden from participating in the planned studies
      limited. The extra interventions compared to routine care, consist of sampling extra blood.
      The pharmacokinetic assessments require placement of one additional intravenous catheter. To
      ensure minimal impact of study participation on daily life, a limited sampling strategy will
      be used. Patients may benefit from participating in IMPROVE I and -II, as they will be
      treated with a potentially safe and effective drug that is dosed individually, which prevents
      toxic exposure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure (AUC)</measure>
    <time_frame>24 hours</time_frame>
    <description>mg*h/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The fraction (percentage) of patients with attainment of therapeutic exposure with BSA-based dosing versus renal function-based dosing.</measure>
    <time_frame>3 months</time_frame>
    <description>The fraction (percentage) of patients with attainment of therapeutic exposure defined as an AUC of 164 mg*h/l ±25%, with pemetrexed dosing based on renal function versus BSA-based dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Population Clearance (Cl)</measure>
    <time_frame>3 months</time_frame>
    <description>L/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Intercompartmental Clearance (Q)</measure>
    <time_frame>3 months</time_frame>
    <description>L/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Central Volume of Distribution (V1)</measure>
    <time_frame>24 hours</time_frame>
    <description>L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Peripheral Volume of Distribution (V2)</measure>
    <time_frame>3 months</time_frame>
    <description>L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of different renal function algorithms to predict pemetrexed</measure>
    <time_frame>3 months</time_frame>
    <description>Significant change in objective function value (OFV) (&lt;3.84 with 1 degree of freedom)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of different renal function algorithms to predict pemetrexed pharmacokinetics (decrease in variability)</measure>
    <time_frame>3 months</time_frame>
    <description>Decrease in clearance variablity (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic assessment during dosing based on renal function in patients with a creatinine clearance &gt;45ml/min versus dosing based on BSA.</measure>
    <time_frame>5 days</time_frame>
    <description>Complete blood count (no per liter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hematologic dose limiting toxicities (DLT) and adverse events, as measured with the CTCAE V4'</measure>
    <time_frame>3 months</time_frame>
    <description>through listing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of non-hematologic dose limiting toxicities (DLT) and adverse events, as measured with the CTCAE V4</measure>
    <time_frame>3 months</time_frame>
    <description>through listing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of toxicity-related dose reductions, treatment delays and treatment discontinuation</measure>
    <time_frame>3 months</time_frame>
    <description>through listing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with the EORTC QLQ-C30/L13 questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>0-100 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In silico evaluation of neutropenic response</measure>
    <time_frame>1 year</time_frame>
    <description>Simulation of risk for neutropenic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutropenia related costs</measure>
    <time_frame>1 year</time_frame>
    <description>Euros</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Arm A (BSA-based dosing)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing of pemetrexed is based on BSA according drug label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (renal function based dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Dosing is either based on BSA or renal function</description>
    <arm_group_label>Arm A (BSA-based dosing)</arm_group_label>
    <arm_group_label>Arm B (renal function based dosing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years old

          2. Eligible for treatment with pemetrexed-based chemotherapy

          3. Creatinine clearance &gt;45ml/min

          4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2

          5. Subject is able and willing to sign the Informed Consent Form

        Exclusion Criteria:

          1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be
             assessed by physician)

          2. Contraindications for treatment with pemetrexed in line with the summary of product
             characteristics (SmPC) (except for creatinine clearance &lt;45 ml/min in IMPROVE-I)

               1. Hypersensitivity to the active substance or to any of the excipients

               2. Pregnancy or lactation

               3. Concomitant yellow fever vaccine

          3. The presence of clinically relevant pharmacokinetic interactions, according to the
             current SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob ter Heine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rob ter Heine, PhD</last_name>
    <phone>+31 (0)24 361 7744</phone>
    <email>R.terHeine@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki de Rouw, MSc</last_name>
    <phone>+31 (0)24 361 7744</phone>
    <email>Nikki.deRouw@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonne Biesma</last_name>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Bonne Biesma</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeroen Derijks</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sjaak Burgers</last_name>
      <email>s.burgers@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Sjaak Burgers</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alwin Huitema</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Dingemans</last_name>
      <email>a.dingemans@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Dingemans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud university medical centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob ter Heine</last_name>
      <email>R.terHeine@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Rob ter Heine</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikki de Rouw</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel van den Heuvel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Aerts</last_name>
      <email>j.aerts@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Joachim Aerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Mathijsen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

